Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477487 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain
A Phase 1 study of Osteoarthritis, Knee, sponsored by Xalud Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT03477487: Completed Phase 1 study of Osteoarthritis, Knee, sponsored by Xalud Therapeutics.
NCT03477487 is a Phase 1 study of Osteoarthritis, Knee that has completed, run by Xalud Therapeutics. The registered enrollment target is 32 participants, below the 497-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03477487, a Phase 1 study of Osteoarthritis, Knee, has completed, sponsored by Xalud Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of Safety, Tolerability, and Efficacy of XT-150, a plasmid DNA with a variant of human IL-10 transgene. XT-150 will be a single injection into the knee synovial capsule for the Treatment of Osteoarthritic Pain.
Primary Outcome
Clinical, laboratory measures of safety by CTCAE v4.0
Conditions Studied
Interventions
- BIOLOGICAL XT-150
Study Locations (1)
California
- Neurovations (Napa Pain Institute) - Napa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-06-08 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 1 |
What the finished NCT03477487 record still lists
NCT03477487 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 497-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 1 intervention - of which XT-150 is the first listed.
NCT03477487 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03477487 about?
NCT03477487 is a clinical study titled "Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain". Evaluation of Safety, Tolerability, and Efficacy of XT-150, a plasmid DNA with a variant of human IL-10 transgene. XT-150 will be a single injection into the knee synovial capsule for the Treatment of Osteoarthritic Pain.
What is the current status of trial NCT03477487?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-06-08. Estimated completion is 2019-09-30.
What conditions does trial NCT03477487 study?
This clinical trial studies the following conditions: Osteoarthritis, Knee.
What interventions are being tested in trial NCT03477487?
The interventions under investigation include: XT-150 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03477487?
This trial is sponsored by Xalud Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03477487 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis, Knee
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03477487's enrollment target sits among peer trials
32 99th of 112 higher than 14 of 112 other Osteoarthritis, Knee trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis, Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
CBD for Knee Osteoarthritis
RECRUITING · Phase 1
-
Oral Steroid Taper After Total Knee Arthroplasty
RECRUITING · Phase 1
-
The Role of Vitamin K on Knee Osteoarthritis Outcomes
RECRUITING · Phase 1
-
Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
ACTIVE NOT RECRUITING · Phase 1
-
Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI